Navigation Links
Enzyme allows B cells to resist death, leading to leukemia

B cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in adults and is characterized by the progressive accumulation of mature B lymphocytes in the blood, bone marrow, and lymphatic tissues. It is believed that in the early stages of disease, B-CLL is the result of an undefined defect in the programmed signals that trigger normal B cell death (apoptosis). Livio Trentin and colleagues from Padua University School of Medicine now demonstrate that high levels of expression and altered cellular location of an enzyme in B cells known as Lyn, contributes to the development of B-CLL.

The authors examined leukemia cells from 40 patients with B-CLL and compared them with lymphocytes from normal donors. They found that Lyn was markedly overexpressed in CLL cells and an unusual amount of the enzyme was found in the cell cytosol. In addition, the enzyme was constantly active compared with levels of activity in normal donor cells. The authors went on to show that inhibition of Lyn was able to restore the process of cell apoptosis to normal and treatment of malignant cells with drugs that induce cell death decreased both Lyn expression levels and activity ?suggesting a direct correlation between high Lyn activity and the ability of these B cells to resist apoptosis. The authors suggest that Lyn is involved in the development of B-CLL and that this enzyme therefore represents an attractive target for therapy. The study will appear online on January 13 in advance of publication in the February 1 print edition of the Journal of Clinical Investigation.
'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
2. Novel Enzyme Shows Potential As An Anti-HIV Target
3. Enzyme shown to help protect genomic stability
4. Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
5. Enzymes newly discovered role may make it target for arthritis treatment
6. Promiscuous Catalytic Activity Possessed by Novel Enzyme Structure
7. Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Enzyme affects hypertension by controlling salt levels in body
10. Enzyme inhibitors block replication of SARS virus
11. Enzyme crystal structure reveals unexpected genome repair functions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... Aviva Systems Biology Corporation (ASB) which ... GenWay Biotech Incorporated, a protein solutions and applications ... for both the research and diagnostic markets. ... capabilities for both entities. GenWay,s 18 years of experience ... complement ASB,s objective to become a leading provider ...
Breaking Biology Technology: